WST WEST PHARMACEUTICAL SERVICES INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 105770 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.6%
TTM net income YoY29.9%
TTM EPS YoY32.0%
Revenue 3-yr CAGR5.1%
Net income 3-yr CAGR4.5%
Margins
Gross margin37.6%
Operating margin23.0%
Net margin18.8%
FCF margin13.3%
EBITDA margin28.4%
Returns
ROE21.2%
ROA15.6%
ROIC (approx.)23.0%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets26.9%
Debt / equity0.07x
Current ratio2.82x
Interest coverage96.32x
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio-0.4%
Payout ratio9.8%
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.07B | $2.89B |
| Cost of revenue | $1.97B | $1.89B |
| Gross profit | $1.10B | $998.50M |
| R&D expense | $74.30M | $69.10M |
| SG&A expense | $393.60M | $338.50M |
| Operating income | $584.90M | $569.90M |
| Interest expense | $500,000 | $3.00M |
| Pretax income | $600.90M | $585.50M |
| Income tax | $121.60M | $107.50M |
| Net income | $493.70M | $492.70M |
| EBITDA | $756.30M | $725.30M |
| EPS (basic) | 6.83 | 6.75 |
| EPS (diluted) | 6.79 | 6.69 |
| Dividends declared per share | 0.86 | 0.82 |
| Weighted avg. shares (diluted) | 72.70M | 73.70M |
| Balance sheet | ||
| Cash & equivalents | $791.30M | $484.60M |
| Receivables | $574.40M | $552.50M |
| Inventory | $443.90M | $377.00M |
| Current assets | $1.98B | $1.54B |
| PP&E, net | $1.73B | $1.58B |
| Goodwill | $109.90M | $106.00M |
| Intangibles | $7.70M | $10.80M |
| Total assets | $4.27B | $3.64B |
| Current liabilities | $654.90M | $550.40M |
| Short-term debt | $0 | $0 |
| Long-term debt | $202.80M | $202.60M |
| Total debt | $202.80M | $202.60M |
| Total liabilities | $1.09B | $961.10M |
| Shareholders' equity | $3.18B | $2.68B |
| Net debt | -$588.50M | -$282.00M |
| Shares outstanding | 72.00M | 72.30M |
| Cash flow statement | ||
| Operating cash flow | $754.80M | $653.40M |
| Capital expenditure | $285.90M | $377.00M |
| Free cash flow | $468.90M | $276.40M |
| Investing cash flow | -$285.90M | -$378.70M |
| Financing cash flow | -$185.10M | -$622.60M |
| Depreciation & amortization | $171.40M | $155.40M |
| Stock-based compensation | $23.80M | $18.70M |
| Dividends paid | $61.20M | $59.10M |
| Share buybacks | $134.00M | $560.90M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.